Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps3-27-08 | Thyroid Cancer clinical 3 | ETA2023

Lymph nodes metastases from papillary thyroid microcarcinoma negatively impact on outcome

Contarino Andrea , Dolci Alessia , Arosio Maura

Background: Papillary thyroid microcarcinoma (microPTC), defined as PTC measuring 10 mm or less in greatest diameter, is the most common type of thyroid cancer. MicroPTC generally has an indolent clinical course, with slow and exclusivelly intrathyroidal growth, without any significant impact on patient morbidity and mortality of patients. Sometimes, even microPTC can show lymph nodes (LNs) involvement, ranging from incidental histological findings to preoperative evidence of ...

ea0081p200 | Thyroid | ECE2022

Thyroid dysfunction related to SARS-CoV-2 vaccination: the experience of a single center in Milan

Muller Ilaria , Di Marco Francesco , Arosio Maura , Salvi Mario

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic disease (Covid-19) has caused millions of deaths worldwide, thus a massive SARS-CoV-2 vaccination campaign has been launched since the end of 2020. Viruses and vaccines can induce adverse thyroid effects; SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT) and Graves’ disease (GD). We aimed to study the occurrence o...

ea0041oc13.1 | Pituitary Clinical | ECE2016

Acromegaly is associated with increased cancer risk: a nationwide survey in Italy on behalf of the Italian study group of acromegaly

Reimondo Giuseppe , Terzolo Massimo , Berchialla Paola , Malchiodi Elena , Arosio Maura

Introduction: That acromegaly may cause cancer remains an unsolved issue. Aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in a nationwide multicenter cohort study in Italy on acromegalic patients who have been treated in the somatostatin-receptor ligands era.Methods and design: We have evaluated the prevalence of neoplasia from a series of 1512 patients who were proactively followed in 24 terti...

ea0081oc8.4 | Oral Communications 8: Calcium and Bone | ECE2022

Is the “rebound phenomenon” following Denosumab discontinuation a risk factor for Zoledronic acid acute phase adverse reactions?

Zampogna Marta , Grassi Giorgia , Ghielmetti Alberto , Palmieri Serena , Arosio Maura , Vainicher Cristina Eller

Background: Zoledronic acid (ZOL) administration may cause acute phase adverse reactions (APR), which manifest with fever, malaise, bone and muscular pain, headache and/or gastrointestinal disturbances. Previous data suggest that high N-terminal propeptide of type 1 collagen (P1NP) and low 25, OH-vitaminD (VitD) levels are associated with higher incidence of APR, while the previous use of bisphosphonates is a protective factor. Lately, ZOL has been frequently used to mitigate ...

ea0081yi5 | Young Investigator Awards | ECE2022

Pseudohypoparathyroidism: focus on neonatal features, preliminary data from a retrospective analysis of a large cohort of patients

Del Sindaco Giulia , Pagnano Angela , Berkenou Jugurtha , Rothenbuhler Anya , Arosio Maura , Linglart Agnes , Mantovani Giovanna

Since the first description of pseudohypoparathyroidism (PHP) a remarkable clinical variability was observed. In 2016 a new classification of this group of diseases have been published by the European Network on PHP and related disorders, proposing “inactivating PTH/PTHrP signaling disorder” (iPPSD) as a new term that encompasses all the clinical entities. PHP and related disorders vary in clinical presentation and disease severity, and clinical features usually deve...

ea0081p558 | Calcium and Bone | ECE2022

Clinical and biochemical response to Burosumab treatment in two patients with X-linked hypophosfatemic rickets and tertiary hyperparathyroidism

Ghielmetti Alberto , Zampogna Marta , Palmieri Serena , Grassi Giorgia , Rosa Caruso Maria , Arosio Maura , Vainicher Cristina Eller

Introduction: in X-linked hypophosfatemic rickets (XLH) mutations of PHEX lead to elevated FGF-23 levels. Phosphate salts and calcitriol represented the only treatment option. Tertiary hyperparathyroidism (THPT) is a complication of XLH worsening the clinical features and constituting a contraindication to conventional treatment. Burosumab, a monoclonal antibody anti-FGF23, was recently approved in XLH. No data about Burosumab treatment in patients with XLH and THPT are availa...

ea0081p659 | Pituitary and Neuroendocrinology | ECE2022

Evaluation of copeptin levels during glucagon stimulation test in children with suspected growth hormone deficiency

Ferrante Emanuele , Giacchetti Federico , Indirli Rita , Profka Eriselda , Rodari Giulia , Giavoli Claudia , Mantovani Giovanna , Arosio Maura

Introduction: Glucagon stimulation test is one of the recommended growth hormone provocation tests for diagnosing growth hormone deficiency in children. In adult patients, recent data showed that glucagon administration is able to stimulate the release of copeptin, the stable C-terminal glycopeptide of the AVP prohormone whose evaluation during hypertonic saline infusion represents the gold standard for the differential diagnosis of polyuria/polydipsia. However, similar data o...

ea0084ps1-01-08 | COVID & Thyroid Disease | ETA2022

Graves’ orbitopathy and subacute thyroiditis related to SARS-CoV-2 infection or vaccination: the experience of a single centre in milan, italy

Muller Ilaria , Crivicich Erica , Di Marco Francesco , Curro Nicola , Arosio Maura , Salvi Mario

Background: The Covid-19 pandemic caused by the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) determined millions of deaths worldwide, thus at the end of 2020 a massive vaccination campaign has been launched. SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT), Graves’ disease (GD) and orbitopathy (GO). We studied the occurrence of SAT and GO following SARS-CoV-2 infection or vaccinati...

ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alemtuzumab-induced graves’ orbitopathy successfully treated with a single dose of rituximab

Di Marco Francesco , Porcaro Laura , Crivicich Erica , Curro Nicola , Arosio Maura , Muller Ilaria , Salvi Mario

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...

ea0090rc4.6 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Bone and sexual health in adult women with complete androgen insensivity syndrome: A single centre experience

Profka Eriselda , Rodari Giulia , Giacchetti Federico , Giavoli Claudia , Arosio Maura , Mantovani Giovanna

Background: Low bone mineral density (BMD) and reduced sexual satisfaction have been reported in complete androgen insensitivity syndrome (CAIS). Nevertheless, conclusive data on the prevalence and on the optimal management of these conditions are still lacking.Aims: To assess bone and sexual health in adult women with CAIS with and without gonadectomy.Methods: Single-centre, prospective study of 27 adult CAIS (age 35.2±8.7 ye...